Mutant ZIP8 mice exhibited systemic Mn deficiency, with significant reductions in Mn levels in whole blood, liver, and kidney (Sunuwar et al., 2020)
The relevance of these findings to humans has not been determined
Would love to hear your thoughts #Pharma #PharmaIndustry #Healthcare #GLP1 #Semaglutide #DiabetesCare #ObesityCare #IndianPharma #PharmaStrategy #HealthcareInnovation #ChronicCare #MarketTrends #BusinessStrategy #PharmaMarketing #FutureOfHealthcare To view or add a comment, sign in The last week in Indian Pharma was all about semaglutide
Step 1: Direct Akkermansia Support Supporting Akkermansia levels is one of the most impactful steps you can take for gut barrier and intestinal lining health during GLP-1 treatment
Most common side effects Compounded Liraglutide has not been evaluated by the FDA, but Liraglutide-based medications reviewed by the FDA have the following side effects: nausea, diarrhea, vomiting, constipation, abdominal (stomach) pain, headache, fatigue, dyspepsia (indigestion), dizziness, abdominal distension, eructation (belching), hypoglycemia (low blood sugar) in patients with type 2 diabetes, flatulence (gas buildup), gastroenteritis (an intestinal infection), and gastroesophageal reflux disease
While 5-Amino-1MQ is relatively robust, the stability of its active form within the GI tract versus in a reconstituted injectable solution is always a point of discussion